chartexchange

BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026

PR Newswire | Nov 16, 2026 7:00 AM EST

- Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting - - GLIX1 demonstrated robust, dose-dependent antitumor activity in multiple GBM models, including confirmed evidence of brain penetration and...

Read original article